Gencurix Corrects Asset Transfer Completion Report for Nanobio Life Share Sale – Payment Schedule Revised and Responsible Person Changed
Gencurix amended its asset transfer completion report dated December 26, 2024, revising the payment schedule for the sale of 903,753 common shares of its subsidiary Nanobio Life to Ciclid.
The total consideration of 5,639,418,720 KRW remains unchanged, but the fourth installment of 500,000,000 KRW due June 30, 2026, has been eliminated, and the final balance due December 24, 2026, increased from 1,944,418,720 KRW to 2,444,418,720 KRW.
The correction includes a change in the payment schedule and the responsible person, with no new share issuance, appraisal rights, or creditor protection matters.
[AI Summary]This amendment adjusts the payment schedule for a previously completed asset transfer, with no impact on total transaction size or financial statements. The market impact is negligible, and the event is assessed as neutral.
KOSDAQ Filing Information
[Correction of Description] Report on Termination of Merger, etc. (Transfer of Assets)